Evidence map›Paper›PMID 22891239›Full record

ArticleThe Journal of biological chemistry2012

Inhibition of transmitter release and attenuation of anti-retroviral-associated and tibial nerve injury-related painful peripheral neuropathy by novel synthetic Ca2+ channel peptides.

Sarah M Wilson, Brian S Schmutzler, Joel M Brittain, Erik T Dustrude, Matthew S Ripsch, Jessica J Pellman, Tae-Sung Yeum, Joyce H Hurley, Cynthia M Hingtgen, Fletcher A White and 1 more

Open access · hybridAbstract read
In one paragraph

Article in The Journal of biological chemistry, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.

0numbers the graph read from it
0cells of the map it votes in
33citing papers in PubMed
3.5field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

33 citing papers in PubMed, 49 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Hierarchical CRMP2 posttranslational modifications control NaV1.7 function.Proceedings of the National Academy of Sciences of the United States of America · 2016
    Article
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 1 country.

Sarah M WilsonDepartment of Program in Medical Neurosciences, Stark Neurosciences Research Institute, Indiana University School of Medicine, Indianapolis, Indiana 46202.
Brian S SchmutzlerDepartment of Pharmacology and Toxicology, Indiana University School of Medicine, Indianapolis, Indiana 46202.
Joel M BrittainDepartment of Program in Medical Neurosciences, Stark Neurosciences Research Institute, Indiana University School of Medicine, Indianapolis, Indiana 46202.
Erik T DustrudeDepartment of Program in Medical Neurosciences, Stark Neurosciences Research Institute, Indiana University School of Medicine, Indianapolis, Indiana 46202.
Matthew S RipschDepartment of Anesthesia, Indiana University School of Medicine, Indianapolis, Indiana 46202.
Jessica J PellmanDepartment of Pharmacology and Toxicology, Indiana University School of Medicine, Indianapolis, Indiana 46202.
Tae-Sung YeumDepartment of Anesthesia, Indiana University School of Medicine, Indianapolis, Indiana 46202.
Joyce H HurleyDepartment of Program in Medical Neurosciences, Stark Neurosciences Research Institute, Indiana University School of Medicine, Indianapolis, Indiana 46202; Department of Biochemistry and Molecular Biology, Indiana University School of Medicine, Indianapolis, Indiana 46202.
Cynthia M HingtgenDepartment of Program in Medical Neurosciences, Stark Neurosciences Research Institute, Indiana University School of Medicine, Indianapolis, Indiana 46202; Department of Pharmacology and Toxicology, Indiana University School of Medicine, Indianapolis, Indiana 46202; Department of Neurology, Indiana University School of Medicine, Indianapolis, Indiana 46202.
Fletcher A WhiteDepartment of Program in Medical Neurosciences, Stark Neurosciences Research Institute, Indiana University School of Medicine, Indianapolis, Indiana 46202; Department of Anesthesia, Indiana University School of Medicine, Indianapolis, Indiana 46202.
Rajesh KhannaDepartment of Program in Medical Neurosciences, Stark Neurosciences Research Institute, Indiana University School of Medicine, Indianapolis, Indiana 46202; Department of Pharmacology and Toxicology, Indiana University School of Medicine, Indianapolis, Indiana 46202; Department of Biochemistry and Molecular Biology, Indiana University School of Medicine, Indianapolis, Indiana 46202; Sophia Therapeutics LLC, Indianapolis, Indiana 46202. Electronic address: khanna5@iu.edu.
Indiana University – Purdue University Indianapolis · USIndiana University School of Medicine

Funding

INDIANA CLINICAL AND TRANSLATIONAL SCIENCE INSTITUTE (UL1): BPCAUL1RR025761 · NCRR · INDIANA UNIVERSITY INDIANAPOLIS · PI SHEKHAR, ANANTHA · 2008 to 2011
$21.0M
Chemokine-mediated Modulaton of Opioid-induced PainR01DA026040 · NIDA · LOYOLA UNIVERSITY CHICAGO · PI MARCHESE, ADRIANO, WHITE, FLETCHER A · 2008 to 2012
$1.5M
Mechanisms of Neuropathic Pain in Demylenated NervesR01NS049136 · NINDS · LOYOLA UNIVERSITY CHICAGO · PI WHITE, FLETCHER A · 2006 to 2010
$1.3M
NCRR NIH HHS RR025761NCRR NIH HHS UL1 RR025761NIDA NIH HHS DA026040-04NIDA NIH HHS R01 DA026040NINDS NIH HHS NS049136-06NINDS NIH HHS R01 NS049136
6 · The paper itself

Abstract

N-type Ca(2+) channels (CaV2.2) are a nidus for neurotransmitter release and nociceptive transmission. However, the use of CaV2.2 blockers in pain therapeutics is limited by side effects resulting from inhibition of the physiological functions of CaV2.2 within the CNS. We identified an anti-nociceptive peptide (Brittain, J. M., Duarte, D. B., Wilson, S. M., Zhu, W., Ballard, C., Johnson, P. L., Liu, N., Xiong, W., Ripsch, M. S., Wang, Y., Fehrenbacher, J. C., Fitz, S. D., Khanna, M., Park, C. K., Schmutzler, B. S., Cheon, B. M., Due, M. R., Brustovetsky, T., Ashpole, N. M., Hudmon, A., Meroueh, S. O., Hingtgen, C. M., Brustovetsky, N., Ji, R. R., Hurley, J. H., Jin, X., Shekhar, A., Xu, X. M., Oxford, G. S., Vasko, M. R., White, F. A., and Khanna, R. (2011) Suppression of inflammatory and neuropathic pain by uncoupling CRMP2 from the presynaptic Ca(2+) channel complex. Nat. Med. 17, 822-829) derived from the axonal collapsin response mediator protein 2 (CRMP2), a protein known to bind and enhance CaV2.2 activity. Using a peptide tiling array, we identified novel peptides within the first intracellular loop (CaV2.2(388-402), "L1") and the distal C terminus (CaV1.2(2014-2028) "Ct-dis") that bound CRMP2. Microscale thermophoresis demonstrated micromolar and nanomolar binding affinities between recombinant CRMP2 and synthetic L1 and Ct-dis peptides, respectively. Co-immunoprecipitation experiments showed that CRMP2 association with CaV2.2 was inhibited by L1 and Ct-dis peptides. L1 and Ct-dis, rendered cell-penetrant by fusion with the protein transduction domain of the human immunodeficiency virus TAT protein, were tested in in vitro and in vivo experiments. Depolarization-induced calcium influx in dorsal root ganglion (DRG) neurons was inhibited by both peptides. Ct-dis, but not L1, peptide inhibited depolarization-stimulated release of the neuropeptide transmitter calcitonin gene-related peptide in mouse DRG neurons. Similar results were obtained in DRGs from mice with a heterozygous mutation of Nf1 linked to neurofibromatosis type 1. Ct-dis peptide, administered intraperitoneally, exhibited antinociception in a zalcitabine (2'-3'-dideoxycytidine) model of AIDS therapy-induced and tibial nerve injury-related peripheral neuropathy. This study suggests that CaV peptides, by perturbing interactions with the neuromodulator CRMP2, contribute to suppression of neuronal hypersensitivity and nociception.

Indexed as

AIDS-Associated NephropathyAnimalsCalcitonin Gene-Related PeptideCalciumCalcium Channels, N-TypeGanglia, SpinalHumansMiceMice, KnockoutMice, Mutant StrainsNeurofibromatosis 1Neurofibromin 1NeuronsNeurotransmitter AgentsNociceptionPeptidesCACNA1B protein, humanCacna1b protein, mouseCalcitonin Gene-Related PeptideCalciumCalcium Channels, N-TypeNeurofibromin 1Neurotransmitter AgentsPeptidesRecombinant Fusion Proteinstat Gene Products, Human Immunodeficiency Virus

Identifiers

PMID22891239
PMCPMC3471755
OpenAlexW1968114963

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.